MP01-16 IL-10 AND CXCL10 URINE QUANTIFICATION AS USEFUL BIOMARKERS TO PREDICT BCG RESPONSE IN BLADDER CANCER PATIENTS

Abstract

You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology I (MP01)1 Apr 2020MP01-16 IL-10 AND CXCL10 URINE QUANTIFICATION AS USEFUL BIOMARKERS TO PREDICT BCG RESPONSE IN BLADDER CANCER PATIENTS Felix Guerrero-Ramos*, Pablo Abad-Lopez, Cristian Suarez-Cabrera, Marta Rodriguez-Izquierdo, Carmen Gomez-Cañizo, Federico de la Rosa-Kehrmann, Victor Garcia-Martinez, Alejandra Bernardini, Iris Lodewijk, Guillermo Paramio, Alfredo Rodriguez-Antolin, Jesus M Paramio, and Marta Dueñas Felix Guerrero-Ramos*Felix Guerrero-Ramos* More articles by this author , Pablo Abad-LopezPablo Abad-Lopez More articles by this author , Cristian Suarez-CabreraCristian Suarez-Cabrera More articles by this author , Marta Rodriguez-IzquierdoMarta Rodriguez-Izquierdo More articles by this author , Carmen Gomez-CañizoCarmen Gomez-Cañizo More articles by this author , Federico de la Rosa-KehrmannFederico de la Rosa-Kehrmann More articles by this author , Victor Garcia-MartinezVictor Garcia-Martinez More articles by this author , Alejandra BernardiniAlejandra Bernardini More articles by this author , Iris LodewijkIris Lodewijk More articles by this author , Guillermo ParamioGuillermo Paramio More articles by this author , Alfredo Rodriguez-AntolinAlfredo Rodriguez-Antolin More articles by this author , Jesus M ParamioJesus M Paramio More articles by this author , and Marta DueñasMarta Dueñas More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000815.016AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Identifying biomarkers to predict BCG response before beginning the treatment is an unsolved need in the clinical practice for patients with high risk non-muscle invasive bladder cancer. Nowadays, there is no method to predict BCG response in our patients. In this context, protumor activity of M2 macrophages could be mediating this treatment response, so evaluation of cytokines as IL-10 and CXCL10 in urine could be an indicator of their activity on patient’s urothelium. The main aim of this work is to evaluate if expression levels of IL-10 and CXCL10 in urine samples obtained before treatment are able to identify BGC responders and non-responders. We also aimed to find out the correlation of these levels in urine with the presence of M2 macrophages in tumor tissue samples obtained after transurethral resection of the bladder tumor (TURBT) and before the onset of BCG instillations. METHODS: Tumor tissue samples as well as urine samples were collected from a paired sample set (n= 20) from patients before BCG treatment at our Urology Department. Response to BCG instillations was defined as no recurrence after 2 years. Informed consent was obtained from all patients. The expression levels of IL-10 and CXCL10 were measured by ELISA and RT-qPCR. The percentage of M2 polarized macrophages was calculated by immunohistochemistry staining using CD163 as M2 surface marker. We also carried out nanostring profiling with IO360 panel to characterize immune cell population in tumor tissue. RESULTS: We found a good correlation between the levels of IL-10 and CXCL10 measured by ELISA in urine samples and the levels determined by RT-qPCR in urine and tumor tissue. In order to define if the presence of M2 macrophages before BCG instillation correlates with the BCG response rate, we quantified CD163-positive cells in tissue samples from responders and non-responders. We found that patients with higher count of CD163+ infiltrating cells show worse response to BCG. We found that IL-10 quantification is a good predictor for BCG response. CONCLUSIONS: The presence of M2 polarized macrophages in TURBT tissue as well as M2 markers in urine samples of bladder cancer patients appear to be predictive for BCG response. However, validation in a larger cohort is needed to confirm our data. Source of Funding: None. © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e8-e8 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Felix Guerrero-Ramos* More articles by this author Pablo Abad-Lopez More articles by this author Cristian Suarez-Cabrera More articles by this author Marta Rodriguez-Izquierdo More articles by this author Carmen Gomez-Cañizo More articles by this author Federico de la Rosa-Kehrmann More articles by this author Victor Garcia-Martinez More articles by this author Alejandra Bernardini More articles by this author Iris Lodewijk More articles by this author Guillermo Paramio More articles by this author Alfredo Rodriguez-Antolin More articles by this author Jesus M Paramio More articles by this author Marta Dueñas More articles by this author Expand All Advertisement PDF downloadLoading ...